Revolution Medicines Announces Commencement of Public Offering of Common Stock
March 01, 2023 16:17 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress
February 27, 2023 16:05 ET
|
Revolution Medicines, Inc.
Early clinical data on RMC-6236 provided in support of RAS(ON) Inhibitor platform validation Additional data releases for RMC-6236 (RASMULTI) and RMC-6291 (KRASG12C) expected in 2023 RMC-9805...
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2022 After Market Close on February 27, 2023
February 21, 2023 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
Revolution Medicines to Participate in Upcoming Investor Conferences
February 02, 2023 07:00 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Revolution Medicines to Present at 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023 07:00 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Revolution Medicines Announces Publication Describing Design and Synthesis of RMC-5552, a First-in-Class, Bi-Steric mTORC1-Selective Inhibitor
December 19, 2022 07:00 ET
|
Revolution Medicines, Inc.
Findings Published in the Journal of Medicinal Chemistry Demonstrate Compound’s Exceptional Selectivity for mTORC1 over mTORC2 Tumor Regressions Observed During Combination Treatment with a Bi-Steric...
Revolution Medicines to Regain Global Rights to RMC-4630 following Sanofi’s Termination of SHP2 Inhibitor Development and Commercialization Collaboration
December 07, 2022 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Revolution Medicines to Participate in Upcoming Investor Conferences
November 09, 2022 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress
November 07, 2022 16:05 ET
|
Revolution Medicines, Inc.
Dose escalation ongoing in Phase 1/1b trials evaluating two RAS(ON) Inhibitor drug candidates, RMC-6236 (RASMULTI inhibitor) and RMC-6291 (KRASG12C inhibitor) Completed successful equity financing to...
Revolution Medicines to Report Financial Results for Third Quarter 2022 After Market Close on November 7, 2022
November 01, 2022 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...